as well as AstraZeneca and partner Sanofi’s SNY respiratory syncytial virus (“RSV”) antibody Beyfortus (nirsevimab). AstraZeneca records 50% share of gross profits on sales of Beyfortus in ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

AstraZeneca and Sanofi are leading the charge here with nirsevimab, a long-acting antibody designed to provide passive protection to infants through their first RSV season with a single dose.

Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025. The healthcare company has beaten earnings estimates in three ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy ...

ASTRAZENECA plans to hire more than 800 employees in Singapore including engineering, technical services and global supply chain roles at its upcoming US$1.5 billion manufacturing facility in Tuas ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,267.00 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...